Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX) assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRXFree Report) in a research note published on Sunday morning. The firm issued a sell rating on the stock.

A number of other equities analysts have also recently issued reports on MBRX. Maxim Group cut their price objective on Moleculin Biotech from $45.00 to $20.00 and set a buy rating for the company in a report on Tuesday, March 26th. Roth Mkm reaffirmed a buy rating and set a $40.00 price target on shares of Moleculin Biotech in a research report on Friday, April 12th.

Read Our Latest Research Report on MBRX

Moleculin Biotech Trading Down 5.4 %

MBRX opened at $4.35 on Friday. The stock has a 50-day moving average price of $6.81 and a 200-day moving average price of $8.05. Moleculin Biotech has a 12-month low of $4.28 and a 12-month high of $15.75. The stock has a market capitalization of $9.69 million, a P/E ratio of -0.32 and a beta of 1.95.

Institutional Trading of Moleculin Biotech

A hedge fund recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRXFree Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned about 0.17% of Moleculin Biotech at the end of the most recent quarter. Institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

(Get Free Report)

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.

Featured Articles

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with's FREE daily email newsletter.